High dose (2.5mg) bevacizumab for postradiation cystoid macular oedema
1 April 2017
| Yamini Krishna
|
EYE - Pathology, EYE - Oncology
|
Anti-VEGF, Cystoid macular edema, Melanoma, Radiation damage, Radiotherapy, Tumor
The authors present a retrospective, interventional case series investigating the efficacy of high dose (2.5mg/0.1ml) intravitreal bevacizumab in the treatment of persistent postradiation (Iodine-125 plaque brachytherapy for uveal melanoma) cystoid macular oedema (CME). Persistent CME was defined as increased or...
Retinoblastoma chemotherapeutic drugs and their toxic effects on RPE cells
1 October 2016
| Bheemanagouda Patil
|
Retina / Uvea / Vitreous
|
chemotherapy, intra-ocular tumour, retinal pigment epithelium, retinoblastoma, toxicity
There is reported clinical evidence of retinal pigment epithelium (RPE) alterations after intra-arterial (IAC) and intravitreal chemotherapy (IViC) of retinoblastoma. The purpose of this study was to investigate the cellular toxic effects of melphalan, topotecan and carboplatin on the RPE...
Systemic rituximab immunotherapy in the management of primary ocular adnexal lymphoma single institutional experience
1 October 2015
| Jonathan CP Roos
|
Oculoplastics, Orbit
|
Extranodal marginal zone lymphoma, Rituximab, immunotherapy, lymphoma, ocular adnexa
Ocular adnexal lymphomas constitute 2% of all non-Hodgkin’s disease and 5-15% of all extranodal lymphomas and are usually localised, low-grade and of B-cell origin. This opens them up to potential treatment with a systemic monoclonal antibody-based drug (rituximab) directed at...
Management of diffuse OSSN with topical chemotherapy
1 June 2015
| Anjali Gupta
|
Paediatric Ophthalmology / Strabismus
|
chemotherapy, complication, ocular surface squamous neoplasia
Ocular surface squamous neoplasia (OSSN) can be localised to the conjunctiva or, less commonly, diffusely spread over the conjunctiva and cornea. Localised OSSN can be treated by surgical removal with adjuvant cryotherapy and chemotherapy with low rates of recurrence. Diffuse...
RaScaL Study
1 June 2015
| Sofia Rokerya
|
Retina / Uvea / Vitreous
|
Diabetic macular edema, Fluorescein angiography, Anti-VEGF, Ranibizumab, Laser photocoagulation, Combination therapy, Optical coherence tomography
The RaScaL study was a six month, single-centre, controlled, prospective phase I/II study in which subjects with diabetic macular oedema (DME) and associated peripheral nonperfusion on ultrawide-field fluorescein angiography (UWFA) were randomised to: (1) study arm: ranibizumab (0.5 mg) injection...
Long-term outcomes for hereditary retinoblastoma
1 December 2014
| Nana Theodorou
|
Paediatric Ophthalmology / Strabismus
|
chemotherapy, failure rate, focal therapy, hereditary retinoblastoma, visual acuity
Earlier diagnosis and more rigorous treatment regimens have contributed to better outcomes for patients with retinoblastoma. This study looked at 24 patients with hereditary bilateral retinoblastoma treated with systemic chemotherapy during a ten year period (2001-2011). The medical notes were...
Adjunctive topical 5-FU vs. MMC for surgically excised, localised OSSN
1 October 2014
| Anjali Gupta
|
EYE - Cornea, EYE - General
|
OSSN, chemotherapy, ocular oncology, ocular surface tumours
Ocular surface squamous neoplasia (OSSN) comprises a range of dysplasia including corneal-conjunctival intraepithelial neoplasia and invasive squamous cell carcinoma. The traditional treatment for localised non-invasive OSSN has been surgical excision with or without intraoperative cryotherapy. Postoperative adjunctive topical chemotherapy significantly...
